San Diego, California, United States
NCT Number: NCT01335347
Safety Study of an Oral Vaccine to Prevent Avian Influenza
The purpose of this study is to demonstrate the safety and immunogenicity of an oral vaccine to prevent avian influenza. Volunteers will receive either one or two doses of research vaccine or placebo as part of this study.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year–49 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 1
Primary location
Who can participate
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- In good health as established by medical history, physical examination and laboratory testing at the time of enrollment.
Exclusion criteria
- Has had any other vaccines within the past 8 weeks.
- Has had prior H5 avian influenza investigational vaccine.
- Current history of chronic alcohol consumption and/or illicit and/or recreational drug use.
- History of autoimmune related disease.
- History of any confirmed or suspected immunodeficient or immunosuppressive condition (no congenital or acquired condition that impedes normal immune response, no concurrent immunosuppressive therapy).
- Positive serology for HIV, HCV, or HBV.
- Previous serious reactions to vaccination such as anaphylaxis, respiratory problems, hives or abdominal pain.
- History of irritable bowel disease or other inflammatory digestive or gastrointestinal conditions that could affect the intended distribution or safety evaluation of an orally administered vaccine targeting the mucosa of the small intestine.
- Use of proton pump inhibitors (Nexium, Prilosec) that substantially increases stomach pH.
- Stool sample with occult blood at baseline exam
Treatment and study plan
ND1.1
Biologicaladenovirus with the dsRNA adjuvant, dried and put into capsules
Other names: Ad-HA-dsRNA
Placebo control
BiologicalCapsules of the same size and shape as experimental groups
Primary outcomes
-
Frequency or severity of vaccine related events as measured through reported AEs
Time frame: up to 1 year
Secondary outcomes
-
Magnitude of humoral immune responses to avian influenza as measured by functional assays
Time frame: up to 1 year
-
Magnitude of cellular immune responses to avian influenza as measured by functional assays
Time frame: up to 1 year
Sponsors and collaborators
Lead sponsor
Vaxart
Industry
Registry information
Official study title
A Dose Escalation Phase 1 Safety and Immunogenicity Study of an Oral Viral Vector Vaccine Encoding Avian Influenza H5N1 Hemagglutinin Protein and dsRNA Adjuvant in Healthy Adults
Acronym: H5N1
Important dates
- Study start
- 2011
- Primary completion
- 2012
- Study completion
- 2012
- First posted
- Apr 14, 2011
- Registry last updated
- Jan 3, 2013
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
A Study to Evaluate the Safety and Immunogenicity of Two Doses of a Novel H5 Central Antigen mRNA-LNP in Healthy Adults
NCT07019883
Animal Diseases, Avian Influenza
Durham, North Carolina, United States
View Trial DetailsA Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects ≥18 Years of Age
NCT02839330
Animal Diseases, Avian Influenza
Huntsville, Alabama, United States
View Trial DetailsH7N9 Vaccination With and Without AS03 and Unadjuvanted H3N2v Vaccination: Standard and Systems Biology Analyses
NCT02921997
Animal Diseases, Avian Influenza
Nashville, Tennessee, United States
View Trial DetailsH5N8 Mix and Match With or Without AS03 or MF59 in Healthy Adults: Immunology
NCT03014310
Animal Diseases, Avian Influenza
Atlanta, Georgia, United States
View Trial Details